Sentien Biotechnologies is a clinical stage company developing novel approaches to cell therapy. Its lead product is designed to allow for controlled, sustained delivery of mesenchymal stem cell (MSC) secreted factors. Sentien’s approach immobilizes the MSCs in an extracorporeal device, allowing for doses of therapeutic secreted factors that are unattainable by direct injection.
© 2020 Pappas Capital, LLC. ALL RIGHTS RESERVED.